Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 29 от 222

Recruiting

Economic-demographic Assessment of the Aseptic Mobilization of Knee Prostheses Through the RIPO Registry and Radiographic Analysis of the Case Series From the II Clinic of IOR

Aseptic Loosening Arthropathy of Knee

The increase in life expectancy is leading to an increase in the average age of patients undergoing total knee arthroplasty (TKA), and, consequently, an increase in the number of revisions. The main cause of TKA failure is aseptic mobilization, which is described as the loss of integration between the prosthetic component and the bone in the absence of infection. This represents a significant impact on professional and economic resources for the Italian healthcare system. Aseptic mobilization can be caused by inadequate initial fixation of the implant and/or mechanical or biological loss of fixation over time, factors that often occur simultaneously. A careful, methodical evaluation of post-operative radiographs of TKAs remains an important diagnostic tool. The analysis of the causes of aseptic mobilization of TKAs and the associated economic impact in the Emilia Romagna region is useful for providing an estimate of the problem and identifying potential areas for improvement.

Начало: 18.03.2026 Край: 31.12.2026 Възраст: от 18 г.

Italy Istituto Ortopedico Rizzoli NCT06821581

Recruiting Phase 1

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Obesity Overweight

The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.

Начало: 18.03.2026 Край: 01.02.2027 Възраст: 18–65 г.

United States Eli Lilly and Company NCT07476118

Recruiting

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

Coronary Artery Disease Chronic Coronary Syndrome Acute Coronary Syndrome

The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.

Начало: 18.03.2026 Край: 31.12.2029 Възраст: от 19 г.

South Korea Samsung Medical Center NCT07329699

Recruiting

Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years

Myopia Progression

The goal of this clinical investigation is to learn how much a new generation of myopia control lens (MCL1 - Myopia Control Lens 1) is helpful in reducing myopia progression in children from 6 to 14 yo. The main questions it aims to answer is: How much this new generation of lens, called MCL1, slows down the growth of the eye? Researchers will compare MCL1 to a former generation of myopia control lens (i.e. MCL2) but with better vision quality. Participants will: * Wear MCL1 on right eye and MCL2 on left eye for 6 months and MCL2 on rigth eye and MCL1 on left eye for the next 6 months; * Visit the hospital at 6 and 12 months for tests; * Answer weekly questionnaires on compliance wearing glasses, quality of vision and out-of-school activities.

Начало: 18.03.2026 Край: 01.05.2028 Възраст: 6–14 г.

France Essilor International NCT07462897

Recruiting Phase 2

Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)

Postoperative Analgesia After Unilateral Hip Arthroplasty

This is a phase IIa, multicenter ,randomized, double-blind, Double-Dummy, Active- and placebo-controlled study designed to evaluate the efficacy, safety and kinetic characteristics of TRD205 tablets for postoperative analgesia after unilateral hip arthroplasty

Начало: 18.03.2026 Край: 27.07.2026 Възраст: 18–80 г.

China Beijing Tide Pharmaceutical Co., Ltd NCT07543796

Recruiting

Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performance of Children With Cerebral Palsy

Cerebral Palsy

Cerebral palsy is a common neurological disorder that is the leading cause of motor disability in children. It causes significant motor impairments, affecting various aspects such as fine and gross motor skills, as well as locomotion, which has a major impact on the quality of life of affected children. It is therefore essential to characterize these functional impairments in order to guide clinical decisions and maximize the motor function of affected children. Currently, the assessment of motor function is based on physical examinations and functional scales, such as the Gross Motor Function Classification System, which is specifically designed to assess children with CP. However, movement analysis using optoelectronic systems is considered the gold standard for this assessment, even though these systems have notable limitations (expensive installation, time-consuming use, and use only in a clinical environment, making it difficult to assess motor skills in children's everyday lives). In order to establish a comprehensive and personalized functional diagnosis, it is crucial to evaluate other fundamental motor tasks such as running, jumping, object control, and balance tasks. Recently, innovative markerless motion analysis technologies have been developed that allow analysis using smartphones or tablets outside of healthcare facilities. Therefore, developing an application dedicated to motion analysis for children with cerebral palsy that is easy to access and can be used frequently could yield many significant benefits.

Начало: 18.03.2026 Край: 16.11.2028 Възраст: 6–18 г.

France Centre Hospitalier Universitaire Dijon NCT07432789

Recruiting Phase 3

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Non-small Cell Lung Cancer

This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.

Начало: 18.03.2026 Край: 26.10.2039 Възраст: от 18 г.

Taiwan, Ukraine Merck Sharp & Dohme LLC NCT07431827

Recruiting Phase 3

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

Osteogenesis Imperfecta

The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.

Начало: 18.03.2026 Край: 21.05.2028 Възраст: 5–19 г.

Germany, United States Amgen NCT07366086

Recruiting Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH)

Trial status: Authorised Occurrence of Treatment-Emergent Adverse Events (TEAEs), Severity of TEAEs, Change from baseline in circulating N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) concentrations, Change from baseline in mean pulmonary artery pressure, Change from baseline in cardiac output, Change from baseline in cardiac index, Change from baseline in right atrial pressure, Change from baseline in 6-Minute Walk Distance (6MWD), Concentrations of functional REGN13335 in plasma, Concentrations of total soluble Platelet-Derived Growth Factor-B (PDGF-B) ligands in plasma Change from baseline in Pulmonary Vascular Resistance (PVR)

Начало: 18.03.2026 Възраст: от 18 г.

Belgium, Czech Republic, France +4 Regeneron Pharmaceuticals Inc. 2024-514754-79-00

Recruiting

Popliteal Nerve Block for Acute Achilles Tendon Rupture Repair Surgery

Acute Achilles Tendon Rupture

Achilles tendon rupture is common, yet the value of popliteal nerve block for postoperative pain control during surgical repair remains uncertain. Despite widespread use, evidence supporting its analgesic effectiveness is limited, and both popliteal nerve block and Achilles tendon repair carry risks of nerve injury. This randomized, placebo-controlled trial will evaluate whether adding a popliteal nerve block to standard systemic analgesia improves postoperative pain and reduces opioid use in patients undergoing acute Achilles tendon rupture repair. Secondary outcomes will examine the incidence and impact of nerve complications on recovery, including return to physical activity and functional performance.

Начало: 17.03.2026 Край: 01.03.2028 Възраст: 18–65 г.

Canada Women's College Hospital NCT06886815

Recruiting Phase 1/2

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Solid Tumours

The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.

Начало: 17.03.2026 Край: 29.03.2030 Възраст: 18–130 г. Treatment

Australia, Japan, South Korea +3 AstraZeneca NCT07446855

Recruiting Phase 1

Alnuctamab for Refractory SLE (LATTE Study)

Systemic Lupus Erythematosus

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

Начало: 17.03.2026 Край: 01.12.2027 Възраст: 18–60 г.

United States Icahn School of Medicine at Mount Sinai NCT07219563

Recruiting Phase 1/2

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

ER+, HER 2- Breast Cancer Non-small Cell Lung Cancer (NSCLC) Castration-resistant Prostate Cancer (CRPC) Microsatellite Stable (MSS) Colorectal Carcinoma

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.

Начало: 17.03.2026 Край: 30.06.2030 Възраст: 18–99 г.

United States IDEAYA Biosciences NCT07540572

Recruiting Phase 3

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Varicella (Chickenpox) Chickenpox Vaccine

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

Начало: 17.03.2026 Край: 01.07.2036 Възраст: 12–12 г.

Thailand GC Biopharma Corp NCT07054099

Recruiting Phase 1

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

Alpha 1 Antitrypsin Deficiency

This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.

Начало: 17.03.2026 Край: 01.01.2029 Възраст: 18–74 г. Treatment

Australia, Georgia, United Kingdom AIRNA Corporation NCT07431112

Recruiting Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Epstein-Barr Virus

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Начало: 17.03.2026 Край: 15.05.2027 Възраст: 18–30 г. Prevention

Australia ModernaTX, Inc. NCT07478952

Recruiting Phase 1

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Solid Tumors (Phase 1)

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Начало: 17.03.2026 Край: 14.03.2029 Възраст: от 18 г. Treatment

Australia, United States Adcendo ApS NCT07362888

Recruiting Phase 2

SHIELD – Swift Hydrocortisone Intervention after trauma exposure

Posttraumatic Stress Disorder (PTSD)

Trial status: Authorised Status of PTSD diagnosis at 3 months (T4) after the intervention, measured with the CAPS-5., Self-reported PTSD symptom severity at 2 weeks (T1), 1 month (T2), 6 weeks (T3), 3 months (T4), 6 months (T5) and 12 months (T6) after the intervention, measured with the PCL-5., Scores on the questionnaires assessing other outcomes (IDS-SR, EQ-5D-5L, AUDIT, ISI) and SAEs at T1 to T6., Demographic data, scores on questionnaires (CTQ, LEC-5), wearable measuring heart rate (HR) and heart rate variability (HRV), intrusion and sleep diary, saliva sample collected at intake, self-composed questionnaires., Results of qualitative interviews with 20 participants of the trial PTSD symptom severity at 3 months (T4) after the intervention, measured with the CAPS-5 score.

Начало: 17.03.2026 Възраст: 18–64 г.

Netherlands Amsterdam UMC Stichting 2025-523350-13-02

Recruiting

Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With Obesity

Obesity Metabolic Syndrome

This study evaluates whether a fruit- and vegetable-based fermented product (Rutazyme® lemon fermented product) taken as a capsule can improve metabolic health in adults with obesity. Forty adults aged 18-65 years with obesity (BMI ≥ 27 kg/m² and waist circumference \> 90 cm for men or \> 80 cm for women) will be randomly assigned to receive either a Rutazyme® lemon fermented product capsule (500 mg) or a placebo capsule once daily at bedtime for 12 weeks. Before supplementation, participants will complete a 2-week stabilization period during which they maintain their usual diet and physical activity. Body composition and waist/hip measurements will be assessed during the study, and blood pressure will be monitored. Blood samples will be collected to evaluate metabolic and safety laboratory measures (e.g., lipids, glucose, insulin, inflammation markers, liver and kidney function), and stool samples will be collected to assess gut microbiota. Gut-brain axis biomarkers (GLP-1 and PYY) will be measured at multiple time points after capsule intake at baseline and at Week 12. The results will help determine the metabolic effects and safety of Rutazyme® lemon fermented product supplementation in adults with obesity.

Начало: 16.03.2026 Край: 31.08.2026 Възраст: 18–65 г.

Taiwan National Taiwan Sport University NCT07540949

Recruiting Phase 1

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Healthy Participants

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.

Начало: 16.03.2026 Край: 29.05.2026 Възраст: 18–55 г.

United States AstraZeneca NCT07316608

1 … 27 28 29 30 31 … 222